Human Immunodeficiency Virus Type-1 Market Analysis and Forecast to 2033: By Drug Class (Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), Integrase Inhibitor, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), and Region

The Human Immunodeficiency Virus Type-1 market size was USD 36.7 billion in 2023 and is anticipated to reach USD 65.8 billion in 2033, growing at a rate of 6.0% from 2024 to 2033.

Human Immunodeficiency Virus Type-1 (HIV-1) is a retrovirus that causes Acquired Immunodeficiency Syndrome (AIDS). It is a virus that attacks the body’s immune system, making it less able to fight off other infections and diseases. HIV-1 is the most common and pathogenic strain of the virus and is the cause of the majority of HIV infections globally.

HIV-1 is transmitted through contact with bodily fluids, such as semen, vaginal fluid, and blood. This can occur through sexual contact, sharing of needles, or mother to child transmission. It is not spread through casual contact such as hugging, kissing, or touching.

Once HIV-1 enters the body, it begins to replicate and spread to other cells. This process weakens the body’s immune system, leaving it vulnerable to other infections and diseases. Over time, the virus progresses and can eventually lead to AIDS. AIDS is the most advanced stage of HIV infection and is characterized by a weakened immune system and severe health complications.

There is no cure for HIV-1, but there are treatments available to manage the virus and its symptoms. These include antiretroviral therapy (ART) which helps to reduce the amount of virus in the body and slow down its progression. There are also measures that can be taken to reduce the risk of HIV-1 transmission, such as using condoms during sexual contact and not sharing needles.

HIV-1 is a serious virus that can be life-threatening if left untreated. It is important to be aware of the risk factors and take steps to protect yourself and others from infection. With proper treatment and prevention, it is possible to live a long and healthy life with HIV-1.

Market Scope and Report Structure
Report Attribute Details
Historic Period2017-2022
Forecast Period2024-2033
Base Year2023
Segments CoveredDrug Class, Distribution Channel, and Region
Key CompaniesThe market includes players such as Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (US), AstraZeneca (U.K.), GSK plc (UK), Merck & Co. Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Mylan N.V. (US), Sanofi (France), and Bayer AG (Germany).
Regional ScopeNorth America, Europe, Asia Pacific, Latin America, and Middle East and Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Size in 2023$ 36.7 Bn
Growth Rate (2024-33)6.0%
Market Size in 2033$ 65.8 Bn
Key Drivers and Trends

Human Immunodeficiency Virus Type-1 (HIV-1) is a retrovirus that has caused a global pandemic. It is estimated that over 35 million people are currently living with HIV/AIDS, and over 25 million people have died from the disease since its emergence in the early 1980s. The HIV-1 market is a multi-billion dollar industry that is driven by a number of factors. These factors include the increasing prevalence of HIV-1, the need for better treatments and diagnostics, the emergence of new drugs and therapies, and the increasing demand for HIV-1 testing and prevention.

The prevalence of HIV-1 is one of the key drivers of the HIV-1 market. The World Health Organization estimates that there are currently 36.7 million people living with HIV worldwide, with approximately 1.8 million new infections each year. This growing prevalence of HIV-1 has resulted in increased demand for HIV-1 treatments, diagnostics, and prevention.

The need for better treatments and diagnostics is another major driver of the HIV-1 market. Currently, there is no cure for HIV-1, and treatment options are limited. Antiretroviral therapy (ART) is the most effective treatment for HIV-1, but it is often expensive and not always accessible in developing countries. Additionally, there is a need for better HIV-1 diagnostics that can detect HIV-1 infection earlier and more accurately.

The emergence of new drugs and therapies is another key driver of the HIV-1 market. Over the past decade, there have been several new drugs and therapies developed to treat HIV-1, including antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP). These new drugs and therapies have been found to be more effective than existing treatments, resulting in increased demand for them in the HIV-1 market.

The increasing demand for HIV-1 testing and prevention is another major driver of the HIV-1 market. HIV-1 testing is essential for early diagnosis and treatment, and prevention measures such as condom use and needle exchange programs can help reduce the spread of HIV-1. The increasing demand for HIV-1 testing and prevention has resulted in increased demand for HIV-1 testing kits, HIV counseling services, and other HIV-1 prevention services.

Restraints & Challenges

The Human Immunodeficiency Virus Type-1 (HIV-1) is a virus that causes AIDS, a severe and life-threatening condition. HIV-1 is one of the world’s most serious public health challenges. Despite advances in treatment, the virus continues to spread, with an estimated 38 million people living with HIV/AIDS worldwide. Despite the significant potential for growth, there are several key restraints and challenges that are limiting the growth of the HIV-1 market.

First, the cost of HIV-1 treatments is a major barrier to access. Antiretroviral therapy (ART) is the most effective treatment for HIV-1, but it is also expensive and not widely available in low- and middle-income countries. This is due to the high cost of the drugs, as well as the lack of infrastructure to deliver them.

Second, there is a lack of awareness and education about HIV-1. This means that many people do not understand the risks of HIV-1 or how to protect themselves from it. This lack of awareness can lead to people engaging in risky behavior, which can further spread the virus.

Third, there is a lack of access to testing and diagnosis for HIV-1. This means that many people may not know that they are infected until it is too late. This can lead to further spread of the virus and increased mortality. These key restraints and challenges are limiting the growth of the HIV-1 market and preventing access to life-saving treatments. If these issues are not addressed, the HIV-1 epidemic could continue to worsen, leading to increased mortality and suffering.

COVID-19 Impact

Pre-COVID-19 Pandemic Scenario

Before the onset of the COVID-19 pandemic, the Human Immunodeficiency Virus Type-1 (HIV-1) market was marked by steady progress in both research and treatment availability. Significant advancements in ART had improved the quality of life for individuals living with HIV-1. Drug regimens were becoming more effective, less toxic, and easier to adhere to with once-daily single-pill formulations. Global initiatives like the UNAIDS 90-90-90 targets (90% of people living with HIV knowing their status, 90% of diagnosed individuals on treatment, and 90% of those treated achieving viral suppression) had enhanced access to HIV-1 medications in low- and middle-income countries. The introduction and uptake of pre-exposure prophylaxis (PrEP) had contributed to reducing new infections, particularly among high-risk populations.

COVID-19 Pandemic Scenario

The emergence of COVID-19 in early 2020 had profound and multi-dimentional impacts on the HIV-1 market. These impacts can be categorized into disruptions in healthcare delivery, shifts in research priorities, and changes in market dynamics. Lockdowns and movement restrictions severely disrupted access to healthcare services, including HIV testing, treatment initiation, and routine follow-ups. Many individuals faced challenges in obtaining their medications, leading to concerns about treatment adherence and viral rebound. Healthcare systems, particularly in low-resource settings, were overwhelmed by the COVID-19 response. This diverted resources and attention away from HIV services, affecting the continuity of care for HIV-1 patients. Many ongoing clinical trials for HIV-1 treatments and vaccines were paused or delayed as research institutions and pharmaceutical companies reallocated resources to COVID-19 studies. The pandemic accelerated the adoption of telemedicine and remote care models, which provided a way to maintain contact with patients while minimizing the risk of COVID-19 transmission. These models showed potential for broader application in chronic disease management, including HIV-1.

Post-COVID-19 Pandemic Scenario

As the world begins to recover from the COVID-19 pandemic, the HIV-1 market is experiencing both challenges and opportunities. Clinical trials that were paused during the pandemic have resumed, with some studies incorporating new methodologies developed during the COVID-19 era. There is renewed focus on innovative treatments, including long-acting therapies and vaccines. The successful implementation of telemedicine during the pandemic has encouraged its continued use. Remote monitoring and virtual consultations are becoming integral parts of HIV care, improving accessibility for patients who face barriers to in-person visits.

Market Segmentation

The market can be segmented by drug class, distribution channel, and region.

Human Immunodeficiency Virus Type-1 Market By Drug Class

By Drug Class, the market can be divided into Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), Protease Inhibitors (PIs), Integrase Inhibitor, and Others. The Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) segment dominated the market in 2023 and it is anticipated to be the fastest during the forecast period. The growth is attributed to the development of new formulations aimed at improving patient adherence, such as fixed-dose combinations and long-acting injectable NRTIs. Additionally, there is a focus on reducing side effects and enhancing drug tolerability, which is critical for long-term treatment. Innovations in personalized medicine and pharmacogenomics are also influencing the NRTIs market, allowing for more tailored and effective treatment plans for individuals living with HIV-1.

Human Immunodeficiency Virus Type-1 Market By Distribution Channel

By Distribution Channel, the market can be divided into Hospital Pharmacies and Retail Pharmacies. The Hospital Pharmacies segment dominated the market in 2023 and it is anticipated to be the fastest during the forecast period. The centralized access to comprehensive healthcare services, which ensures timely and reliable delivery of antiretroviral therapies. Hospital pharmacies are integral in managing complex HIV treatment regimens, offering specialized care and adherence support critical for patient outcomes. Additionally, the integration of advanced digital health technologies for better inventory management and patient tracking, and the increased collaboration with outpatient services to enhance continuity of care. Additionally, there is a growing emphasis on personalized medicine, with hospital pharmacies playing a pivotal role in tailoring treatments based on individual patient profiles.

Human Immunodeficiency Virus Type-1 Market By Region

By Region, the market is divided into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America has dominated the regional segment in 2023 and Asia Pacific is anticipated to be the fastest growing region in the coming years. The high healthcare expenditure, advanced healthcare infrastructure, and significant investment in research and development. The region benefits from strong governmental support and policies aimed at improving access to HIV treatment and prevention services. Also, the adoption of innovative treatment options such as long-acting injectables and dual therapy regimens. There is also a notable increase in the use of telehealth services for HIV care, driven by the COVID-19 pandemic. Additionally, public health initiatives focusing on awareness and early diagnosis are enhancing market growth.

Key Players

The market includes players such as Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (US), AstraZeneca (U.K.), GSK plc (UK), Merck & Co. Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Mylan N.V. (US), Sanofi (France), and Bayer AG (Germany).

Recent Developments
  • In November 2023, HOOKIPA Pharma Inc., a company specializing in innovative immunotherapies using its proprietary arenavirus platform, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-500. HB-500 is a new arenaviral therapeutic vaccine aimed at treating HIV. HOOKIPA will manage the HIV program through the completion of a Phase 1b clinical trial, after which Gilead holds the exclusive right to take over further development.
Human Immunodeficiency Virus Type-1 Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Human Immunodeficiency Virus Type-1 Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of Human Immunodeficiency Virus Type-1 Market in terms of revenue ($Million).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Human Immunodeficiency Virus Type-1 industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country market analysis is also presented in this report.
  • Analytical depiction of the Human Immunodeficiency Virus Type-1 Market along with the current trends and future estimations to depict imminent investment pockets. The overall Human Immunodeficiency Virus Type-1 industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Human Immunodeficiency Virus Type-1 Market are also analyzed.
Frequently Asked Questions

Q1. How big is the Human Immunodeficiency Virus Type-1 Market?

Ans: The Human Immunodeficiency Virus Type-1 market size was USD 36.7 billion in 2023 and is anticipated to reach USD 65.8 billion in 2033, growing at a rate of 6.0% from 2024 to 2033.

Q2. What is the Human Immunodeficiency Virus Type-1 Market growth rate?

Ans. The growth rate of the Human Immunodeficiency Virus Type-1 Market is 6.0%

Q3. Which region holds a major market share for the market?

Ans. North American holds a major market share in 2023.

Q4. Which segment accounted for the largest Human Immunodeficiency Virus Type-1 Market share?

Ans. By drug class, the Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) segment accounted for the largest Human Immunodeficiency Virus Type-1 Market share in 2023.

Q5. Who are the key players in the Human Immunodeficiency Virus Type-1 Market?

Ans. The market includes players such as Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (US), AstraZeneca (U.K.), GSK plc (UK), Merck & Co. Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Mylan N.V. (US), Sanofi (France), and Bayer AG (Germany).

Q6. What is the factor driving the Human Immunodeficiency Virus Type-1 Market growth?

Ans. The major factor driving the growth of the market are prevalence of HIV-1, and the need for better treatments and diagnostics.

Q7. What are the key growth strategies of Human Immunodeficiency Virus Type-1 Market players?

Ans. The key growth strategies of Human Immunodeficiency Virus Type-1 Market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Human Immunodeficiency Virus Type-1 Market during the forecast period?

Ans. The Asia Pacific region will provide more business opportunities for the Human Immunodeficiency Virus Type-1 Market during the forecast period.

Why GIS?

Table of Contents

Chapter 1. Human Immunodeficiency Virus Type-1 Market Overview
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Limitations
1.4. Years & Currency Considered in the Study
1.5. Research Methodologies
1.5.1. Secondary Research
1.5.1.1. Data Collection
1.5.1.2. List of Secondary Sources
1.5.1.3. Key Data from Secondary Sources
1.5.2. Primary Research
1.5.2.1. List of Primary Research Sources
1.5.3. Market Size Estimation: Top-Down Approach
1.5.4. Market Size Estimation: Bottom-Up Approach
1.5.5. Data Triangulation and Validation

Chapter 2. Executive Summary
2.1. Summary
2.2. Key Opinion Leaders
2.3. Key Highlights of the Market, by Drug Class
2.4. Key Highlights of the Market, by Distribution Channel

Chapter 3. Premium Insights on the Market
3.1. Market Attractiveness Analysis, by Region
3.2. Market Attractiveness Analysis, by Drug Class
3.3. Market Attractiveness Analysis, by Distribution Channel

Chapter 4. Human Immunodeficiency Virus Type-1 Market Outlook
4.1. Human Immunodeficiency Virus Type-1 Market Segmentation
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.1.1. Driver 1
4.2.1.2. Driver 2
4.2.1.3. Driver 3
4.2.2. Market Restraints
4.2.2.1. Restraint 1
4.2.2.2. Restraint 2
4.2.3. Market Opportunities
4.2.3.1. Opportunity 1
4.2.3.2. Opportunity 2
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Buyers
4.3.4. Bargaining Power of Supplier
4.3.5. Competitive Rivalry
4.4. PESTLE Analysis
4.5. Value Chain Analysis
4.5.1. Raw Material Suppliers
4.5.2. Manufacturers
4.5.3. Wholesalers and/or Retailers
4.6. Impact of COVID-19 on the Human Immunodeficiency Virus Type-1 Market
4.7. Impact of the Russia and Ukraine War on the Human Immunodeficiency Virus Type-1 Market
4.8. Case Study Analysis
4.9. Pricing Analysis

Chapter 5. Human Immunodeficiency Virus Type-1 Market, by Drug Class
5.1. Market Overview
5.2. Non- nucleoside reverse transcriptase inhibitors (NNRTIs)
5.2.1. Key Market Trends & Opportunity Analysis
5.2.2. Market Size and Forecast, by Region
5.3. Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)
5.3.1. Key Market Trends & Opportunity Analysis
5.3.2. Market Size and Forecast, by Region
5.4. Protease Inhibitors (PIs)
5.4.1. Key Market Trends & Opportunity Analysis
5.4.2. Market Size and Forecast, by Region
5.5. Integrase Inhibitor
5.5.1. Key Market Trends & Opportunity Analysis
5.5.2. Market Size and Forecast, by Region
5.6. Others
5.6.1. Key Market Trends & Opportunity Analysis
5.6.2. Market Size and Forecast, by Region

Chapter 6. Human Immunodeficiency Virus Type-1 Market, by Distribution Channel
6.1. Market Overview
6.2. Hospital Pharmacies
6.2.1. Key Market Trends & Opportunity Analysis
6.2.2. Market Size and Forecast, by Region
6.3. Retail Pharmacies
6.3.1. Key Market Trends & Opportunity Analysis
6.3.2. Market Size and Forecast, by Region

Chapter 7. Human Immunodeficiency Virus Type-1 Market, by Region
7.1. Overview
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. North America Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.2.3. North America Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.2.4. North America Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Country
7.2.5. The U.S.
7.2.5.1. The U.S. Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.2.5.2. The U.S. Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.2.6. Canada
7.2.6.1. Canada Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.2.6.2. Canada Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.2.7. Mexico
7.2.7.1. Mexico Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.2.7.2. Mexico Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Europe Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.3. Europe Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.4. Europe Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Country
7.3.5. The U.K.
7.3.5.1. The U.K. Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.5.2. The U.K. Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.6. Germany
7.3.6.1. Germany Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.6.2. Germany Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.7. France
7.3.7.1. France Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.7.2. France Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.8. Spain
7.3.8.1. Spain Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.8.2. Spain Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.9. Italy
7.3.9.1. Italy Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.9.2. Italy Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.10. Netherlands
7.3.10.1. Netherlands Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.10.2. Netherlands Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.11. Sweden
7.3.11.1. Sweden Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.11.2. Sweden Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.12. Switzerland
7.3.12.1. Switzerland Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.12.2. Switzerland Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.13. Denmark
7.3.13.1. Denmark Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.13.2. Denmark Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.14. Finland
7.3.14.1. Finland Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.14.2. Finland Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.15. Russia
7.3.15.1. Russia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.15.2. Russia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.3.16. Rest of Europe
7.3.16.1. Rest of Europe Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.3.16.2. Rest of Europe Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Country
7.4.3. Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.4. Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.5. China
7.4.5.1. China Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.5.2. China Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.6. India
7.4.6.1. India Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.6.2. India Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.7. Japan
7.4.7.1. Japan Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.7.2. Japan Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.8. South Korea
7.4.8.1. South Korea Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.8.2. South Korea Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.9. Australia
7.4.9.1. Australia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.9.2. Australia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.10. Singapore
7.4.10.1. Singapore Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.10.2. Singapore Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.11. Indonesia
7.4.11.1. Indonesia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.11.2. Indonesia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.12. Taiwan
7.4.12.1. Taiwan Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.12.2. Taiwan Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.13. Malaysia
7.4.13.1. Malaysia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.13.2. Malaysia Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.4.14. Rest of APAC
7.4.14.1. Rest of APAC Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.4.14.2. Rest of APAC Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.5. Rest of The World
7.5.1. Key Market Trends and Opportunities
7.5.2. Rest of The World Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.5.3. Rest of The World Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.5.4. Rest of The World Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Country
7.5.5. Latin America
7.5.5.1. Latin America Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.5.5.2. Latin America Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.5.6. Middle East
7.5.6.1. Middle East Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.5.6.2. Middle East Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel
7.5.7. Africa
7.5.7.1. Africa Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Drug Class
7.5.7.2. Africa Human Immunodeficiency Virus Type-1 Market Size and Forecast, by Distribution Channel

Chapter 8. Competitive Landscape
8.1. Market Overview
8.2. Market Share Analysis/Key Player Positioning
8.3. Developmental Strategy Benchmarking
8.3.1. New Product Development
8.3.2. Product Launches
8.3.3. Business Expansions
8.3.4. Partnerships, Joint Ventures, And Collaborations
8.3.5. Mergers And Acquisitions

Chapter 9. Company Profiles
9.1. HUF. Hoffmann-La Roche Ltd. (Switzerland)
9.1.1. Company Snapshot
9.1.2. Financial Performance
9.1.3. Product Offerings
9.1.4. Key Strategic Initiatives
9.1.5. SWOT Analysis
9.2. Bristol-Myers Squibb Company (US)
9.2.1. Company Snapshot
9.2.2. Financial Performance
9.2.3. Product Offerings
9.2.4. Key Strategic Initiatives
9.2.5. SWOT Analysis
9.3. AstraZeneca (U.K.)
9.3.1. Company Snapshot
9.3.2. Financial Performance
9.3.3. Product Offerings
9.3.4. Key Strategic Initiatives
9.3.5. SWOT Analysis
9.4. GSK plc (UK)
9.4.1. Company Snapshot
9.4.2. Financial Performance
9.4.3. Product Offerings
9.4.4. Key Strategic Initiatives
9.4.5. SWOT Analysis
9.5. Merck & Co. Inc. (U.S.)
9.5.1. Company Snapshot
9.5.2. Financial Performance
9.5.3. Product Offerings
9.5.4. Key Strategic Initiatives
9.5.5. SWOT Analysis
9.6. Novartis AG (Switzerland)
9.6.1. Company Snapshot
9.6.2. Financial Performance
9.6.3. Product Offerings
9.6.4. Key Strategic Initiatives
9.6.5. SWOT Analysis
9.7. Pfizer Inc. (US)
9.7.1. Company Snapshot
9.7.2. Financial Performance
9.7.3. Product Offerings
9.7.4. Key Strategic Initiatives
9.7.5. SWOT Analysis
9.8. Sun Pharmaceutical Industries Ltd. (India)
9.8.1. Company Snapshot
9.8.2. Financial Performance
9.8.3. Product Offerings
9.8.4. Key Strategic Initiatives
9.8.5. SWOT Analysis
9.9. Mylan N.V. (US)
9.9.1. Company Snapshot
9.9.2. Financial Performance
9.9.3. Product Offerings
9.9.4. Key Strategic Initiatives
9.9.5. SWOT Analysis
9.10. Sanofi (France)
9.10.1. Company Snapshot
9.10.2. Financial Performance
9.10.3. Product Offerings
9.10.4. Key Strategic Initiatives
9.10.5. SWOT Analysis

*The List of Company Is Subject To Change During The Final Compilation of The Report
Key Players
Market Segments

By Drug Class

  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)
  • Protease Inhibitors (PIs)
  • Integrase Inhibitor
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

The global Digital Genome Market was valued at…
Molecular cytogenetics is a field of genetics that…
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect…
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a…
Irritable bowel syndrome (IBS) is a group of…
The global Endocrine Testing Market was valued at…
CBD Pouches are a novel way to consume…
Pulmonary Arterial Hypertension (PAH) is a rare, progressive…
Urticaria is an itchy rash that appears on…
Pancreatic cancer arises when cells in the pancreas…